Healthcare Industry News: Carbomedics
News Release - April 4, 2006
Sorin Group Launches the New Cobalt Chrome Carbostent: CHRONO(TM)CHRONO(TM) Received CE Mark and is Now Available on the Market
MILAN, Italy, April 4 (HSMN NewsFeed) -- Sorin Group, Europe's largest medical technology company specialized in the treatment of cardiovascular diseases, announced that today received CE Mark approval for its new Cobalt Chrome Coronary Carbostent: the CHRONO(TM) stent. CHRONO(TM) will be fully released in Europe and all the CE mark countries.
Since its recent introduction as a revolutionary new material for coronary stents, Cobalt Chrome has demonstrated excellent characteristics including higher mechanical strength and radiopacity than stainless steel. The advantages of CHRONO(TM)are further enhanced by a new stent design engineered to provide more flexibility, and a new state of the art delivery system PTS (Progressive Transition System), which is designed to ensure reliable access to distal and tortuous anatomies. Furthermore, the two radiopaque markers at each end of the stent guarantee accurate placement at the target lesion. To further enhance the performance and benefits of the stent, CHRONO(TM) is coated with Carbofilm(TM), Sorin proprietary coating that has demonstrated to improve haemo- and bio-compatibility of the stent and to reduce the risk of stent thrombosis in a number of registries and randomized trials.
CHRONO(TM) features extremely thin struts and the lowest crossing profile, providing excellent flexibility without compromising radial strength and a new tapered tip giving excellent crossability. The first implants performed across Europe have already demonstrated the unique benefits of CHRONO(TM) in the treatment of complex and distal anatomies. "The CHRONO(TM)stent has shown excellent procedural performance even in complex and challenging lesions, where deliverability is a main issue" said Prof. Bartorelli, (Centro Cardiologico Monzino, Milan).
Initial results from Stellar, a European multicenter randomized clinical trial with the new CHRONO(TM)stent, have already demonstrated an excellent safety profile of the new platform as well as high procedural performance.
"CHRONO(TM) is the only Cobalt chrome stent combining the proven and long term clinical benefits from Carbofilm(TM) coating platform, with superior flexibility, precise positioning and best in class deliverability, designed to redefining performance of Cobalt Chrome Stents" said Stefano Di Lullo, President, Vascular Therapy. He added: "We are very pleased that Sorin 's latest innovation, the CHRONO(TM) stent, is now available to European patients and physicians".
Sorin Group (Reuters code: SORN.MI), a world leader in the development of medical technologies for cardiac surgery, offers innovative therapies for cardiac rhythm dysfunctions, interventional cardiology and the treatment of chronic kidney diseases. Sorin Group includes: Dideco, Carbomedics, COBE Cardiovascular, Stockert, Mitroflow, ELA Medical, Sorin Biomedica, Bellco and Soludia. Sorin Group has more than 4,700 employees working at facilities in more than 80 countries throughout the world to serve over 5,000 public and private treatment centers.
For additional information, please visit our website: www.sorin.com
Source: Sorin Group
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.